[A study on the anti-metastatic effects of CD3Ak cells in nude mice].
To investigate whether cancer draining lymph node lymphocytes activated by CD3 McAB in vitro have anti-tumor effects in vivo. Nude mice with highly metastatic human ovarian cancer were treated with CD3 McAB activated killer cells (CD3AK) from human ovarian cancer draining lymph node lymphocytes. 31 experimental nude mice were divided into 4 groups; the cisplatin group (7 mice), the CD3AK cells group (7 mice), the combined treatment group (7 mice), and control group (10 mice). Treatment began on the 10th day after tumor transplantation for a total of 80 days. The transplanted tumors disappeared in 1 mouse of CD3AK group, significant difference in the anti-metastatic effect was found between the CD3AK group (2/7 mice with metastasis) and the control group (8/10 mice with metastasis). Significant difference in average tumor volume was found between the CD3AK group (0.5788 +/- 0.2549) and the control group (1.5685 +/- 0.283). The tumor growth inhibition rate reached 63.1% in the CD3AK group. Significant difference in the serum level of progesterone was found between the CD3AK group (3.3843 +/- 0.5314) and the control group (6.3480 +/- 0.7615). Significant difference in the histiocyte increase in the lymph node sinuses was found between the CD3AK group (59/69) and the control group (55/94). These results suggest that CD3AK cells appear to be effective in tumor growth inhibition, anti-metastasis and enhancing host immunologic function.